Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
Nouscom
company
About
Nouscom are a biotech company working to develop a series of new, potent immunotherapeutics capable of selectively killing tumor cells.
- 1 - 10
Highlights
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- €42M
- Industries
- Biotechnology,Genetics,Health Care,Therapeutics
- Founded date
- Jan 1, 2015
- Number Of Employee
- 1 - 10
- Operating Status
- Active
Nouscom are a well established team that has worked together for many years in previous successful enterprises, including IRBM/Merck and Okairos, and are veterans in the field of oncolytic and genetic vaccines. The company is headquartered in Basel, Switzerland and has operations in Rome, Italy.The NousCom team is lead by experienced enterpreneurs that worked together for many years in previous successful enterprises, such as Okairos, under the leadership of Prof. Riccardo Cortese, who conceived the ideas behind those companies.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
€54M
Nouscom has raised a total of
€54M
in funding over 2 rounds. Their latest funding was raised on
Nov 6, 2017 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Nov 6, 2017 | Series B | €42M | 1 | — | — | Detail |
| May 17, 2016 | Series A | €12M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Nouscom is funded by 1 investors.
Versant Ventures
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Versant Ventures
|
— | Series B |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
